• Publications
  • Influence
Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2
LTI of ch14.18/CHO induced effector mechanisms over the entire treatment period, and may therefore emerge as the preferred delivery method of anti-GD2 immunotherapy to NB patients.
Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody
Effective treatment of high-risk neuroblastoma (NB) remains a major challenge in pediatric oncology. Human/mouse chimeric monoclonal anti-GD2 antibody (mAb) ch14.18 is emerging as a treatment option
Full Activation of CD4+ T Cells Early During Sepsis Requires Specific Antigen
The data show that, in sepsis, partial activation of CD4+ T cells is induced by a T-cell receptor–independent pathway, whereas full stimulation and proliferation require a specific antigen.
Long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) activity and efficacy in high-risk relapsed/refractory neuroblastoma patients.
A decreasing degree of morphine usage and low pain scores were observed, and the survival update of the APN311-303 cohort revealed a 1-y & 4-y OS of 94.2±3.2% & 60.9±9.0% (median FU 2.9y [0.7-5.2y]).
Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
Human/mouse chimeric monoclonal antibody (mAb) ch14.18 is directed against disialoganglioside GD2 and has demonstrated activity and efficacy in high-risk neuroblastoma (NB). For the purpose of
Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma
Generation and characterization of a new human/mouse chimeric anti-Id Ab ganglidiximab for active immunotherapy against NB and this Ab may be useful to tailor immune responses to the paratope regions mimicking GD2 overexpressed in NB.
Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.
A validated ELISA method suitable for the assessment of HACA in NB patients treated with ch14.18/CHO is described and it is shown that neither eight freeze-thaw cycles nor storage at room temperature for up to 168h affected HACA stability in serum.
Correlation of killer-cell Ig-like receptor (KIR) haplotypes and Fcγ-receptor polymorphisms with survival of high-risk relapsed/refractory neuroblastoma patients treated by long-term infusion of
This data indicates that down-regulation in the number of receptors expressed on natural killer cells and their ligands on target cells involved in antibody-dependent cell-mediated cytotoxicity (ADCC) may predict outcome in patients with cancer.
Effect of interleukin-2 on long term infusion treatment regimen of ch14.18/CHO antibody on activity in relapsed/refractory neuroblastoma patients.
10563Background: Long-term infusion (LTI) emerges as a promising new delivery method of ch14.18/CHO for relapsed/refractory neuroblastoma patients. The role of concomitant treatment with scIL2 is u...
Abstract A032: Immunotherapy with ch14.18/CHO in combination with IL2 is active and effective in high-risk relapsed/refractory neuroblastoma patients
LTI of anti-GD 2 Ab ch14.18/CHO may have an improved pain toxicity profile and at the same time mediate an effective immune response in patients with high risk relapsed/refractory NB which translates to objective clinical responses and an improved survival.